[Federal Register Volume 62, Number 185 (Wednesday, September 24, 1997)]
[Notices]
[Page 49988]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-25266]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Advisory Committee; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: Dental Plaque Subcommittee Meeting of the
Nonprescription Drugs Advisory Committee.
General Function of the Committee: To provide advice and
recommendations to the agency on FDA regulatory issues.
Date and Time: The meeting will be held on October 29 and 30, 1997,
8:30 a.m. to 5 p.m.
Location: Holiday Inn, The Ballroom, Two Montgomery Village Ave.,
Gaithersburg, MD.
Contact Person: Andrea G. Neal, Center for Drug Evaluation and
Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-443-5455, or FDA Advisory Committee
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC
area), code 12541. Please call the Information Line for up-to-date
information on this meeting.
Agenda: On October 29, 1997, the subcommittee will continue
discussion and/or possibly vote on the safety and effectiveness of: C-
31G, xylitol, and zinc citrate, as well as the following combination
ingredients: (1) Menthol, thymol, eucalyptol, and methyl salicylate;
(2) hydrogen peroxide and povidone iodine; and (3) hydrogen peroxide,
sodium citrate, zinc chloride, and sodium lauryl sulfate. The
subcommittee will also continue discussion of the criteria for over-
the-counter (OTC) antiplaque and antigingivitis combination drug
products. On October 30, 1997, the subcommittee will discuss the final
formulation testing for OTC antiplaque and antigingivitis drug
products, and assignments will be made for the review of foreign
marketing data supporting OTC antiplaque and antigingivitis
ingredients.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the subcommittee.
Written submissions may be made to the contact person by October 15,
1997. Oral presentations from the public will be scheduled on both days
between approximately 9 a.m. and 10 a.m. Time allotted for each
presentation may be limited. Those desiring to make formal oral
presentations should notify the contact person before October 15, 1997,
and submit a brief statement of the general nature of the evidence or
arguments they wish to present, the names and addresses of proposed
participants, and an indication of the approximate time requested to
make their presentation.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: September 15, 1997.
Michael A. Friedman,
Deputy Commissioner for Operations.
[FR Doc. 97-25266 Filed 9-23-97; 8:45 am]
BILLING CODE 4160-01-F
